VNDA — Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenues: $50.5 million in Q2 2026, a 4% decrease from $52.6 million in Q2 2025.
• Net Loss: $62.5 million for Q2 2026, compared to a net loss of $27.2 million in Q2 2025.
• Fanapt Sales: $36 million in Q2 2026, a 23% increase year-over-year.
• Hetlioz Sales: $5.6 million in Q2 2026, a significant 66% decrease from $16.2 million in Q2 2025.
• PONVORY Sales: $7.9 million in Q2 2026, an increase of 12% year-over-year.
• NEREUS Sales: $1 million in Q2 2026, with initial wholesaler stocking of $15.2 million.
• Operating Expenses: $114.3 million in Q2 2026, up from $91.1 million in Q2 2025.

2. Strategic Updates and Business Highlights:

• Product Growth: Continued strong performance for Fanapt, with total prescriptions (TRx) up 31% and new brand prescriptions (NBRx) up 32% year-over-year.
• New Launches: NEREUS launched in May 2026, with a direct-to-consumer strategy initiated via a dedicated website.
• Upcoming Products: BYSANTI is expected to launch in the second half of 2026, with a PDUFA date for Imsidolimab set for December 12, 2026.
• Clinical Trials: Multiple late-stage clinical trials are ongoing, with results expected by the end of 2026 or early 2027.

3. Forward Guidance and Outlook:

• Revenue Guidance: Vanda expects total revenues for 2026 to be between $240 million and $290 million, with a midpoint of $265 million, reflecting a 23% increase from 2025.
• Operating Expenses: Anticipated to decrease significantly starting late 2026 and more substantially in 2027 as clinical trials conclude and commercial activities stabilize.
• Cash Position: As of June 30, 2026, Vanda has $170 million in cash, expected to fund operations through at least the end of 2027.

4. Bad News, Challenges, or Points of Concern:

• Declining Hetlioz Sales: Significant decline in Hetlioz sales due to generic competition and inventory destocking, raising concerns about future revenue stability.
• Increased Losses: The net loss has widened compared to the previous year, indicating ongoing financial pressures.
• Cash Burn: Expected cash burn in 2026 is projected to be greater than in 2025, which may raise concerns about liquidity if revenue growth does not meet expectations.

5. Notable Q&A Insights:

• NEREUS Launch Metrics: Management emphasized the importance of monitoring sales engagement, patient acquisition, and refill metrics to gauge NEREUS's market performance.
• HETLIOZ Hearing: The upcoming administrative hearing regarding HETLIOZ was discussed, with management expressing confidence in their case but acknowledging the uncertainty of the outcome.
• R&D Expense Drivers: Increased R&D expenses were attributed to the ramp-up of multiple phase 3 programs and pre-commercial production costs, which are expected to stabilize as launches occur.

Overall, Vanda Pharmaceuticals is navigating a mixed financial landscape with strong growth in some products but significant challenges in others, particularly with Hetlioz. The company is optimistic about upcoming launches and clinical trial results, while closely monitoring operational expenses and cash flow.